Date: 2014-10-09
Type of information: Presentation of results at a congress
phase:
Announcement: presentation of results at the North American Cystic Fibrosis Conference (NACFC) in Atlanta, USA
Company: Galapagos (Belgium)
Product: novel corrector series including potentiator GLPG1837 and a prototype corrector C18
Action mechanism:
Disease: cystic fibrosis
Therapeutic area: Rare diseases - Genetic diseases
Country:
Trial details:
Latest
news: * On October 9, 2014, Galapagos presented a poster disclosing the discovery process for novel, complementary corrector series that restore the CFTR function in a new way at the North American Cystic Fibrosis Conference in Atlanta, USA. These novel corrector series, both in combination with potentiator GLPG1837, and with GLPG1837 and a prototype corrector C18, restore >40% of healthy function in cells from patients with the most common mutation, delF508. Galapagos plans to enter Phase 1 with potentiator GLPG1837 and select a pre-clinical candidate corrector before end 2014. Earlier this year, Galapagos presented preclinical data on five different Galapagos corrector series that in combination with potentiator GLPG1837 restore up to 60% of healthy function in delF508 patient cells. These compounds have been developed by Galapagos and AbbVie. Last December, the two companies have entered into a global alliance to identify compounds that correct defects in expression of (corrector) and/or increase the activity (potentiator) of the main mutations in the cystic fibrosis transmembrane regulator (CFTR) protein, including the F508del mutation.
